Pharmacological disruption of the lactylation axis (e.g., LDHA inhibition) or modulation of RNA-modifying enzymes (e.g., methyltransferases and demethylases) can effectively reverse tumor-associated metabolic reprogramming and epigenetic dysregulation. Here, LDHA is linked to neoplasm.